Review



rna polymerase ii inhibitor act d  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 99
      Buy from Supplier

    Structured Review

    MedChemExpress rna polymerase ii inhibitor act d
    Rna Polymerase Ii Inhibitor Act D, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1439 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/actinomycin+d+act+d/Actinomycin+D/pm41824452-354-14-22
    Average 99 stars, based on 1439 article reviews
    rna polymerase ii inhibitor act d - by Bioz Stars, 2026-09
    99/100 stars

    Images



    Similar Products

    rna polymerase ii inhibitor act d  (MedChemExpress)
    99
    MedChemExpress rna polymerase ii inhibitor act d
    Rna Polymerase Ii Inhibitor Act D, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/actinomycin+d+act+d/Actinomycin+D/pm41824452-354-14-22
    Average 99 stars, based on 1 article reviews
    rna polymerase ii inhibitor act d - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    actinomycin d act d  (MedChemExpress)
    98
    MedChemExpress actinomycin d act d
    FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or <t>Actinomycin</t> <t>D</t> <t>(Act.D)</t> for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.
    Actinomycin D Act D, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/actinomycin+d+act+d/5-Fluorouracil/pmc12865648-255-4-26
    Average 98 stars, based on 1 article reviews
    actinomycin d act d - by Bioz Stars, 2026-09
    98/100 stars
    		  Buy from Supplier
    actinomycin d act d  (Selleck Chemicals)
    95
    Selleck Chemicals actinomycin d act d
    FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or <t>Actinomycin</t> <t>D</t> <t>(Act.D)</t> for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.
    Actinomycin D Act D, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/actinomycin+d+act+d/Nutlin-3/pmc12865648-255-4-37
    Average 95 stars, based on 1 article reviews
    actinomycin d act d - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    act d  (Selleck Chemicals)
    96
    Selleck Chemicals act d
    FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or <t>Actinomycin</t> <t>D</t> <t>(Act.D)</t> for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.
    Act D, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/actinomycin+d+act+d/Actinomycin+D/pmc12992473-177-16-18
    Average 96 stars, based on 1 article reviews
    act d - by Bioz Stars, 2026-09
    96/100 stars
    		  Buy from Supplier
    transcription inhibitor act d  (Thermo Fisher)
    99
    Thermo Fisher transcription inhibitor act d
    FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or <t>Actinomycin</t> <t>D</t> <t>(Act.D)</t> for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.
    Transcription Inhibitor Act D, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/actinomycin+d+act+d/ACTINOMYCIN+D/pm41318742-275-16-56
    Average 99 stars, based on 1 article reviews
    transcription inhibitor act d - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    accountability act  (Thermo Fisher)
    99
    Thermo Fisher accountability act
    FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or <t>Actinomycin</t> <t>D</t> <t>(Act.D)</t> for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.
    Accountability Act, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/actinomycin+d+act+d/ACTINOMYCIN+D/pm41203082-478-200-243
    Average 99 stars, based on 1 article reviews
    accountability act - by Bioz Stars, 2026-09
    99/100 stars
    		  Buy from Supplier
    bvi business companies act  (Thermo Fisher)
    98
    Thermo Fisher bvi business companies act
    FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or <t>Actinomycin</t> <t>D</t> <t>(Act.D)</t> for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.
    Bvi Business Companies Act, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/actinomycin+d+act+d/ACTINOMYCIN+D/sec_filing____2001794_slash_000121390024102936_slash_ea0222438___f1a3_concorde-66-101-172
    Average 98 stars, based on 1 article reviews
    bvi business companies act - by Bioz Stars, 2026-09
    98/100 stars
    		  Buy from Supplier
    exchange act  (Thermo Fisher)
    98
    Thermo Fisher exchange act
    FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or <t>Actinomycin</t> <t>D</t> <t>(Act.D)</t> for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.
    Exchange Act, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/actinomycin+d+act+d/ACTINOMYCIN+D/sec_filing____97745_slash_000119312513461444_slash_d637258d424b5-510-114-138
    Average 98 stars, based on 1 article reviews
    exchange act - by Bioz Stars, 2026-09
    98/100 stars
    		  Buy from Supplier

    Image Search Results


    FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or Actinomycin D (Act.D) for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.

    Journal: Redox Biology

    Article Title: p53 and fatty acids collaborate to trigger ferroptosis via the FBXO2-FABP5 axis in colorectal cancer

    doi: 10.1016/j.redox.2026.104043

    Figure Lengend Snippet: FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or Actinomycin D (Act.D) for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.

    Article Snippet: Nutlin-3, Cisplatin, 5-fluorouracil (5-FU), actinomycin D (Act.D), Etoposide, Alrizomadlin (APG-115), Olaparib, MG132, Liproxstatin-1 (Lipro-1), Ferrostatin-1 (Ferro-1), RSL3, Z-VAD-FMK, Chloroquine (CQ), and Oxaliplatin (Oxa) were purchased from MedChemExpress (Shanghai, China), Erastin and Arachidonic acid (AA) were purchased from Selleck (Shanghai, China).

    Techniques: Standard Deviation, Expressing, Transfection, Luciferase, Reporter Assay, Activation Assay, ChIP-qPCR

    FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or Actinomycin D (Act.D) for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.

    Journal: Redox Biology

    Article Title: p53 and fatty acids collaborate to trigger ferroptosis via the FBXO2-FABP5 axis in colorectal cancer

    doi: 10.1016/j.redox.2026.104043

    Figure Lengend Snippet: FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or Actinomycin D (Act.D) for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.

    Article Snippet: Nutlin-3, Cisplatin, 5-fluorouracil (5-FU), actinomycin D (Act.D), Etoposide, Alrizomadlin (APG-115), Olaparib, MG132, Liproxstatin-1 (Lipro-1), Ferrostatin-1 (Ferro-1), RSL3, Z-VAD-FMK, Chloroquine (CQ), and Oxaliplatin (Oxa) were purchased from MedChemExpress (Shanghai, China), Erastin and Arachidonic acid (AA) were purchased from Selleck (Shanghai, China).

    Techniques: Standard Deviation, Expressing, Transfection, Luciferase, Reporter Assay, Activation Assay, ChIP-qPCR